| COVID-19: a case for inhibiting IL-17? O Pacha, MA Sallman, SE Evans Nature Reviews Immunology 20 (6), 345-346, 2020 | 315 | 2020 |
| Suprabasal acantholytic dermatologic toxicities associated checkpoint inhibitor therapy: A spectrum of immune reactions from paraneoplastic pemphigus‐like to Grover‐like lesions WS Chen, MT Tetzlaff, H Diwan, R Jahan‐Tigh, A Diab, K Nelson, ... Journal of cutaneous pathology 45 (10), 764-773, 2018 | 40 | 2018 |
| Osteonecrosis secondary to antiphospholipid syndrome: a case report, review of the literature, and treatment strategy W Haque, H Kadikoy, O Pacha, J Maliakkal, V Hoang, A Abdellatif Rheumatology International 30, 719-723, 2010 | 40 | 2010 |
| Treating atopic dermatitis: safety, efficacy, and patient acceptability of a ceramide hyaluronic acid emollient foam O Pacha, AA Hebert Clinical, Cosmetic and Investigational Dermatology, 39-42, 2012 | 28 | 2012 |
| A new paradigm for calculating skin dose KA Gifford, O Pacha, AA Hebert, CL Nelson, SM Kirsner, MT Ballo, ... Brachytherapy 12 (2), 114-119, 2013 | 18 | 2013 |
| Skin reactions to immune checkpoint inhibitors AB Patel, O Pacha Immunotherapy, 117-129, 2018 | 17 | 2018 |
| Skin reactions to immune checkpoint inhibitors AB Patel, O Pacha Immunotherapy, 175-184, 2017 | 15 | 2017 |
| Ecthyma gangrenosum and neutropenia in a previously healthy child O Pacha, AA Hebert Pediatric Dermatology 30 (6), e283-e284, 2013 | 15 | 2013 |
| Medical management of primary hyperparathyroidism with concommitant multiple myeloma Z Fanari, H Kadikoy, W Haque, O Pacha, A Abdellatif Internal Medicine 49 (6), 581-584, 2010 | 15 | 2010 |
| Cutaneous adverse events in 155 patients with metastatic melanoma consecutively treated with anti‐CTLA4 and anti‐PD1 combination immunotherapy: Incidence, management, and … AB Patel, S Farooq, M Welborn, RN Amaria, SY Chon, A Diab, ... Cancer 128 (5), 975-983, 2022 | 14 | 2022 |
| A retrospective case series of 20 patients with immunotherapy-induced bullous pemphigoid with emphasis on management outcomes D Bur, AB Patel, K Nelson, A Huen, O Pacha, R Phillips, M Heberton Journal of the American Academy of Dermatology 87 (6), 1394-1395, 2022 | 11 | 2022 |
| Skin reactions to immune checkpoint inhibitors AB Patel, O Pacha Immunotherapy, 235-246, 2020 | 11 | 2020 |
| Pediatric photosensitivity disorders O Pacha, AA Hebert Dermatologic clinics 31 (2), 317-326, 2013 | 6 | 2013 |
| Torsades de pointes and prolonged QT syndrome in Takotsubo cardiomyopathy O Pacha, H Kadikoy, M Amro, W Haque, A Abdellatif Journal of Cardiovascular Medicine 13 (8), 536-540, 2012 | 6 | 2012 |
| Skin reactions to immune checkpoint inhibitors AB Patel, O Pacha Immunotherapy, 319-330, 2021 | 5 | 2021 |
| Psoriasis flares and rebound phenomenon following exposure and withdrawal of systemic steroids: A systematic review and meta-analysis V Long, YW Yew, NS Chandran, ECE Choi Journal of the American Academy of Dermatology 87 (3), 660-661, 2022 | 4 | 2022 |
| Biologic therapies for checkpoint inhibitor-induced cutaneous toxicities: a single-institution study of 17 consecutively treated patients JJ Lo, MM Heberton, O Pacha, AO Huen, AB Patel Supportive Care in Cancer, 1-6, 2022 | 4 | 2022 |
| A review of beta antagonist treatment for infantile hemangioma. CB Phillips, O Pacha, G Biliciler-Denkta, AA Hebert Journal of Drugs in Dermatology: JDD 11 (7), 826-829, 2012 | 4 | 2012 |
| Alectinib-associated drug reaction with eosinophilia and systemic symptoms syndrome S Farooq, S Narala, O Pacha JAAD Case Reports 6 (12), 1339-1341, 2020 | 3 | 2020 |
| Kaposi's sarcoma in the immunosuppressed NA Reddy, SR Mays, O Pacha Journal of Immunotherapy and Precision Oncology 2 (3), 74-78, 2019 | 3 | 2019 |
Amit K GuptaBCM,UPenn,Univ of Florida, Univ of TexasVerified email at uthscsa.edu
